益生元对炎症性肠病调节机制的研究进展

Progress in Research on Regulatory Mechanism of Prebiotics in Inflammatory Bowel Disease

炎症性肠病(IBD)是一种非特异性的肠道慢性炎症性疾病,其发病机制尚未完全阐明。目前普遍认为肠道微生物群在IBD的发病过程中起有关键作用。益生元是一些可调控肠道微生物群的非消化性食物成分。近年来,越来越多的研究支持益生元在IBD中的有益作用。某些膳食补充的益生元可作为可发酵底物来促进肠道有益菌的生长和代谢活性,增加短链脂肪酸的产生,从而发挥抗炎作用。本文将从传统和新兴的角度对益生元在IBD中的保护作用机制的研究进展作一阐述,从而为其在IBD辅助治疗中的应用提供理论依据。

Inflammatory bowel disease(IBD)is a non⁃specific chronic inflammatory disease of the intestine,and its pathogenesis is not yet been fully elucidated.At present,it is generally believed that gut microbiota plays a key role in the pathogenesis of IBD.Prebiotics are non⁃digestible food ingredients that can regulate the gut microbiota.Recently,more and more studies support the beneficial effect of prebiotics in IBD.Some prebiotics of dietary supplements can be used as fermentable substrates to promote the growth and metabolic activity of intestinal beneficial bacteria and increase the production of short⁃chain fatty acids,thereby exerting anti⁃inflammatory effects.This article reviewed the progress in research on the protective mechanism of prebiotics in IBD from the perspective of traditional and emerging prebiotics and providing a theoretical basis for its application in IBD adjuvant therapy.